• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
PASG

PASG

Passage Bio, Inc.

NASDAQHealthcareBiotechnologyUS

USD5.97

+0.07 (+1.27%)

Rating:C+

Company Profile

CEO

William Chou

IPO Date

2020-02-28

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$5.82

Prev. Close

$5.89

Day Low

$5.81

Day High

$5.98

52W Low

$3.94

52W High

$20.00

Market Cap

$0.02B

Volume

0.03M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentNeutral

Articles

10

Avg Positive

23.0%

Avg Negative

17.8%

Avg Neutral

59.4%

News Feed

Passage Bio Announces Key Executive Appointments

GlobeNewsWire·7/19/2021·↑ positive

Why Passage Bio Shares Are Trading Higher Today

Benzinga·7/1/2021·↑ positive

Passage Bio: Price Reduced, But Without Data, Does Not Look Convincing

Seeking Alpha·6/6/2021·↓ negative

Derrell D. Porter, M.D., Elected to Board of Directors of Passage Bio

GlobeNewsWire·6/1/2021·↑ positive

Passage Bio to Host Virtual R&D Event on May 17

GlobeNewsWire·5/10/2021·↓ negative

Passage Bio, Inc. (PASG) CEO Bruce Goldsmith on Q1 2021 Results - Earnings Call Transcript

Seeking Alpha·5/9/2021·↓ negative

Passage Bio Receives European Commission Orphan Designation for PBKR03 for Treatment of Krabbe Disease

GlobeNewsWire·4/5/2021·↓ negative

Moving Average Crossover Alert: Passage Bio (PASG)

Zacks Investment Research·4/1/2021·↓ negative

Passage Bio Announces First Patient Dosed in Imagine-1 Study of PBGM01 Gene Therapy for Infantile GM1 Gangliosidosis

GlobeNewsWire·4/1/2021·↑ positive

Passage Bio to Participate in Upcoming April Investor Conferences

GlobeNewsWire·3/25/2021·↑ positive